OraSure Technologies Inc
Change company Symbol lookup
Select an option...
OSUR OraSure Technologies Inc
CBLUY China BlueChemical Ltd
NIO NIO Inc
MSFT Microsoft Corp
LMT Lockheed Martin Corp
DD Dupont De Nemours Inc
DOW Dow Inc
CTVA Corteva Inc
CSCO Cisco Systems Inc
AAPL Apple Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Company profile

OraSure Technologies, Inc. (OraSure) is a medical device company that develops, manufactures, and markets medical devices and diagnostic products. The Company's products include molecular sampling kits for the genome and microbiome services and analytics, rapid diagnostics for infectious disease, and tests for substance abuse. OraSure’s segments include Diagnostics segment and Molecular Collection Systems segment. The Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices. The Molecular Solutions business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets.

Price
Delayed
$10.85
Day's Change
-0.0345 (-0.32%)
Bid
--
Ask
--
B/A Size
--
Day's High
10.95
Day's Low
10.65
Volume
(Light)

Today's volume of 182,711 shares is on pace to be much lighter than OSUR's 10-day average volume of 472,968 shares.

182,711

Slone Partners Places Scott Gleason as Senior Vice President Investor Relations and Corporate Communications at OraSure Technologies

4:00 am ET July 29, 2021 (PR Newswire) Print

Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and diagnostics companies, has announced the placement of Scott Gleason as Senior Vice President Investor Relations and Corporate Communications at OraSure Technologies, a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services.

Gleason possesses a range of corporate leadership experience in business development and strategic communications across industries. Most recently he served as Senior Vice President of Investor Relations and Corporate Strategy for Myriad Genetics, a leading specialty diagnostic laboratory focused on genetic testing and precision medicine. Prior to his tenure with Myriad, Gleason was a senior publishing analyst at Stephens, Inc. covering the life science tools and diagnostics industry. Before joining Stephens, Gleason was a United States Air Force aircraft maintenance officer and served in two wartime deployments.

"It was a great pleasure working with the OraSure team over the past several months as they sought and secured a talented and experienced candidate to fill this important position," said Slone Partners CEO Leslie Loveless. "Scott's investor relations background will be a tremendous addition to the OraSure executive suite."

"Scott comes to OraSure with over 20 years of executive leadership experience focused in investment banking, investor relations, corporate communications, and corporate strategy and business development. His extensive experience gives him unique insights that will make him a strong addition to OraSure's executive team as the Company advances its work to help solve the world's greatest health challenges," said Stephen S. Tang, Ph.D., President and CEO of OraSure Technologies.

Gleason received a Bachelor of Science degree in Economics from the U.S. Air Force Academy in Colorado Springs, CO.

ABOUT SLONE PARTNERS Slone Partners delivers the leaders who build amazing and diverse life sciences organizations - People Are Our Science(R). Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, New York, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences companies. To learn more about Slone Partners' value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

ABOUT ORASURE TECHNOLOGIES OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit http://www.orasure.com.

Media Contact

Doug, Gavel, (617) 429-4417, doug.gavel@gmail.com

SOURCE Slone Partners

https://rt.prnewswire.com/rt.gif?NewsItemId=UN57330&Transmission_Id=202107290400PR_NEWS_USPR_____UN57330&DateId=20210729

comtex tracking

COMTEX_390593440/1005/2021-07-29T04:00:10

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.